Bosentan and Extracorporeal Photochemotherapy in Eosinophilic Fasciitis

Pileri, Alessandro; Odorici, Giulia; Giudice, Valeria; Patrizi, Annalisa; Bardazzi, Federico

doi:10.1177/1534734614529651

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Distinguishing features of our case are a higher age at start of treatment (66 years vs. median age of 50), and a considerably longer treatment length (58 months to date). In line with previous reports, ECP was dosed over two consecutive days every 2 weeks for 3 months, after which clinical response was noted and the interval was increased, and the patient experienced a significant corticoid‐sparing effect (Minciullo et al, ; Pileri et al, ; Romano et al, ).…”

Section: Discussionsupporting

confidence: 69%

“…The use of ECP for EF has been previously reported in two case series (Minciullo, Morabito, Mandaglio, Iacopino, & Gangemi, 2006;Romano et al, 2003) and one case report (Pileri, Odorici, Giudice, Patrizi, & Bardazzi, 2014), totaling six patients. Refractory disease, as in our case, was the main indication of use, being considered as first-line therapy in only one patient with post-bone marrow transplant EF (Minciullo et al, 2006).…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Steroid‐resistant eosinophilic fasciitis successfully treated with addition of extracorporeal photopheresis

Partarrieu-Mejías

Weth

Pérez‐Ferriols

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Eosinophilic fasciitis (EF) is an uncommon fibrosing disease of the fascia with characteristic cutaneous and hematologic manifestations. Although EF is most commonly treated with corticosteroids at the beginning, a considerable number of patients show an inadequate response and hence various therapeutic strategies have been tried, including extracorporeal photopheresis (ECP). We describe the case of a 66‐year‐old woman with steroid‐resistant EF that improved significantly after ECP was added to her treatment regimen. To date, only six cases of this therapeutic strategy have been reported in English literature.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 96%

Steroid‐resistant eosinophilic fasciitis successfully treated with addition of extracorporeal photopheresis

Partarrieu-Mejías

Weth

Pérez‐Ferriols

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Photopheresis: Advances and Use in Systemic Sclerosis

Zhou

Choi

2017

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment

2017

View full text Add to dashboard Cite

Although fascial biopsy has classically been considered the gold standard for making a diagnosis of EF, radiologic imaging, particularly magnetic resonance imaging, has been increasingly used for both diagnosis and monitoring of treatment response. Systemic corticosteroids remain the first-line treatment for EF; however, their often prolonged use in the treatment of EF has prompted a search for adjunctive therapies. Methotrexate has emerged as the leading corticosteroid-sparing agent for EF. Since EF was initially described over 40 years ago, important diagnostic and therapeutic progress has been made. Future efforts should be directed at the pursuit of prospective studies including clinical trials and evidence-based guidelines.

show abstract

Bosentan and Extracorporeal Photochemotherapy in Eosinophilic Fasciitis

Cited by 6 publications

References 11 publications

Steroid‐resistant eosinophilic fasciitis successfully treated with addition of extracorporeal photopheresis

Steroid‐resistant eosinophilic fasciitis successfully treated with addition of extracorporeal photopheresis

Photopheresis: Advances and Use in Systemic Sclerosis

Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment

Contact Info

Product

Resources

About